Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers

Gynecologic Oncology

Volumn 122, Issue 2, 2011, Pages 233-237

  Kudoh, Kazuya ^a,b   Takano, Masashi ^a,c   Kouta, Hiroko ^a   Kikuchi, Ryoko ^c   Kita, Tsunekazu ^a,d   Miyamoto, Morikazu ^c   Watanabe, Akio ^c   Kato, Masafumi ^c   Goto, Tomoko ^c   Kikuchi, Yoshihiro ^a  

^a Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

^b National Hospital Organization Nishisaitama Chuo National Hospital   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bevacizumab; Ovarian cancer; Pegylated liposomal doxorubicin; Recurrent; Refractory

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SENSORY NEUROPATHY; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 79960473821     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.04.046     Document Type: Article

References (24)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2007 CA Cancer J Clin 60 2010 277 300
2. F. Bray, A.H. Loos, S. Tognazzo, and C. La Vecchia Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000 Int J Cancer 113 2005 977 990 (Pubitemid 40096878)
3. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Eng J Med 334 1996 1 6 (Pubitemid 26012496)
4. M.A. Bookman, B.E. Greer, and R.F. Ozols Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5 Int J Gynecol Cancer 13 2003 735 740 (Pubitemid 38235216)
5. S.A. Cannistra Cancer of the ovary N Eng J Med 351 2004 2519 2529
6. B.J. Monk, E. Han, C.A. Josephs-Cowan, G. Pugmire, and R.A. Burger Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecol Oncol 102 2006 140 144 (Pubitemid 44056265)
7. J.D. Wright, A. Hagemann, J.S. Rader, D. Viviano, R.K. Gibb, and L. Norris Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 107 2006 83 89 (Pubitemid 43939034)
8. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186 (Pubitemid 350232248)
9. F. Simpkins, J.L. Belinson, and P.G. Rose Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening Gynecol Oncol 107 2007 118 123 (Pubitemid 47464553)
10. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: a gynecologic oncology group (GOG) study J Clin Oncol 28 18 s 2010 suppl; abstr LBA1
11. T. Perren, A.M. Swart, J. Pfisterer, J. Ledermann, A. Lortholary, and G. Kristensen ICON7: A phase III randomized gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) Ann Oncol 21 Suppl. 8 2010 LBA4
12. P.A. Haddad, and K.M. Skubitz Combination of bevacizmab (A) and pegylated-liposomal doxorubicin (PLD) (PLD-A) in sarcoma (SAR) J Clin Oncol 24 18 Suppl 2006 abstr. 9556
13. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 10 Suppl 2003 187s 193s
14. D.K. Armstrong Relapsed ovarian cancer: challenges and management strategies for a chronic disease Oncologist 7 Suppl. 5 2002 20 28
15. T.J. Herzog, and B. Pothuri Ovarian cancer: a focus on management of recurrent disease Nat Clin Pract Oncol 3 2006 604 611 (Pubitemid 44669715)
16. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322 (Pubitemid 32642183)
17. D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, and S.D. McMeekin Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2007 2811 2818 (Pubitemid 47123191)
18. G. Ferrandina, M. Ludovisi, D. Lorusso, S. Pignata, E. Breda, and A. Savarese Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 2008 890 896 (Pubitemid 351398081)
19. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171 (Pubitemid 350237599)
20. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
21. A. Sánchez-Muñoz, C. Mendiola, E. Pérez-Ruiz, C.A. Rodríguez-Sánchez, J.M. Jurado, and L. Alonso-Carrión Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Oncology 79 2010 98 104
22. J.D. Hurt, D.L. Richardson, L.G. Seamon, J.F. Fowler, L.J. Copeland, and D.E. Cohn Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer Gynecol Oncol 115 2009 396 400
23. E.S. Han, and B.J. Monk What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105 2007 3 6 (Pubitemid 46441477)
24. D.L. Richardson, F.J. Backes, J.D. Hurt, L.G. Seamon, L.J. Copeland, and J.M. Fowler Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 118 2010 47 51